Interviews

Alison R. Walker, MD, discusses the background, findings, and clinical significance of a phase 3 trial on chemotherapy with or without oblimersen in older patients with AML.

Gwynn Bebb, PhD, and Amanda J.W. Gibson, BSc, discuss the background, findings, and clinical significance of a retrospective real-world study on ALK-inhibiting targeted therapy in patients with ALK-positive NSCLC.

Gregory T. Kennedy, MD, discusses findings from an original investigation on targeted intraoperative molecular imaging for localizing nonpalpable tumors and quantifying resection margin distances.

Lina van der Straten, MD, PhD, spoke on the findings and significance of a nationwide, population-based study on the risk for SPM development in CLL.

Laura Chow, MD, FRCPC, et al look to target intracranial brain activity in patients with ALK-positive NSCLC.

Dr Frank discusses the findings and significance of a clinical trial on the use of STAT3 inhibitor pyrimethamine in patients with CLL.

MRD has been shown to be a viable assessment indicator for disease outcomes in patients with ALL, according to Selina Luger, MD.

The FDA recently granted BTD to VS-6766, a RAF/MEK inhibitor, plus defactinib, a FAK inhibitor, for the treatment of patients with ovarian cancer.